Evaluation of calcium as an insulin secretagogue in patients with insulinoma

L. M. Brunt; W. G. Dilley; J. R. Farndon

Evaluation of calcium as an insulin secretagogue in patients with insulinoma

L. M. Brunt, W. G. Dilley, J. R. Farndon

Research output: Contribution to journal › Article › peer-review

Abstract

CALCIUM ION (Ca⁺⁺) has been administered as an insulin (IN) secretagogue in doses ranging from 4 to 5 mg/kg/hr over two to five hours in patients with insulinoma (1-4). Some reports (1,2) have indicated a significant increase in plasma IN during the CA⁺⁺ infusion, while others (3,4) have demonstrated no change. We have previously observed, in patients with medullary thyroid carcinoma, that plasma calcitonin levels increased to higher peak levels more quickly following a rapid calcium infusion (RCI) than following a long calcium infusion (LCI). In the present study, fasting and stimulated plasma IN levels were compared in normal controls and in patients with insulinoma administered these two tests.

Original language	English
Pages (from-to)	49-52
Number of pages	4
Journal	Surgical Forum
Volume	VOL. 35
State	Published - Jan 1 1984

Cite this

@article{c8abb7a969624f39ab30e24e81891ccf,

title = "Evaluation of calcium as an insulin secretagogue in patients with insulinoma",

abstract = "CALCIUM ION (Ca++) has been administered as an insulin (IN) secretagogue in doses ranging from 4 to 5 mg/kg/hr over two to five hours in patients with insulinoma (1-4). Some reports (1,2) have indicated a significant increase in plasma IN during the CA++ infusion, while others (3,4) have demonstrated no change. We have previously observed, in patients with medullary thyroid carcinoma, that plasma calcitonin levels increased to higher peak levels more quickly following a rapid calcium infusion (RCI) than following a long calcium infusion (LCI). In the present study, fasting and stimulated plasma IN levels were compared in normal controls and in patients with insulinoma administered these two tests.",

author = "Brunt, {L. M.} and Dilley, {W. G.} and Farndon, {J. R.}",

year = "1984",

month = jan,

day = "1",

language = "English",

volume = "VOL. 35",

pages = "49--52",

journal = "Surgical Forum",

issn = "0071-8041",

}

TY - JOUR

T1 - Evaluation of calcium as an insulin secretagogue in patients with insulinoma

AU - Brunt, L. M.

AU - Dilley, W. G.

AU - Farndon, J. R.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - CALCIUM ION (Ca++) has been administered as an insulin (IN) secretagogue in doses ranging from 4 to 5 mg/kg/hr over two to five hours in patients with insulinoma (1-4). Some reports (1,2) have indicated a significant increase in plasma IN during the CA++ infusion, while others (3,4) have demonstrated no change. We have previously observed, in patients with medullary thyroid carcinoma, that plasma calcitonin levels increased to higher peak levels more quickly following a rapid calcium infusion (RCI) than following a long calcium infusion (LCI). In the present study, fasting and stimulated plasma IN levels were compared in normal controls and in patients with insulinoma administered these two tests.

AB - CALCIUM ION (Ca++) has been administered as an insulin (IN) secretagogue in doses ranging from 4 to 5 mg/kg/hr over two to five hours in patients with insulinoma (1-4). Some reports (1,2) have indicated a significant increase in plasma IN during the CA++ infusion, while others (3,4) have demonstrated no change. We have previously observed, in patients with medullary thyroid carcinoma, that plasma calcitonin levels increased to higher peak levels more quickly following a rapid calcium infusion (RCI) than following a long calcium infusion (LCI). In the present study, fasting and stimulated plasma IN levels were compared in normal controls and in patients with insulinoma administered these two tests.

UR - http://www.scopus.com/inward/record.url?scp=0021622963&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0021622963

SN - 0071-8041

VL - VOL. 35

SP - 49

EP - 52

JO - Surgical Forum

JF - Surgical Forum

ER -

Evaluation of calcium as an insulin secretagogue in patients with insulinoma

Abstract

Other files and links

Fingerprint

Cite this